Part 1 of 2 — How Systemic Policy Shifts Are Straining Medicare Advantage Nationwide
Across the United States, a quiet but significant crisis is unfolding at the intersection of federal policy, private insurance, and local healthcare delivery. Seniors walking into their trusted doctors’ offices or local hospitals are increasingly being met with jarring news: their Medicare Advantage (MA) plan is no longer accepted.
To the casual observer, this looks like corporate greed or provider stubbornness. Major insurance carriers are lowering the fees they pay to doctors and hospital systems, and in response, providers are dropping their MA contracts entirely. But this isn’t an isolated market dispute — it’s the direct, inevitable result of a multi-layered federal “squeeze” that starts at the highest levels of government and trickles down to strain the financial viability of Medicare Advantage on the ground.
Phase 1: The Biden-Era Foundation (v28 & the IRA)
The v28 Risk Adjustment Model
Phased in over three years, the v28 diagnostic coding system severely limits how insurance companies classify patient health risks. By removing or reclassifying hundreds of diagnosis codes, CMS effectively reduced the risk-adjusted benchmark payments that private insurers receive from the federal government.
The Inflation Reduction Act (IRA)
While the IRA successfully capped out-of-pocket prescription drug costs for seniors ($2,000 in 2025 and $2,100 in 2026), it achieved this by shifting a large portion of high-cost catastrophic drug liabilities directly onto insurers’ Part D plans. Under the old system, Medicare covered 80% of catastrophic drug costs, while insurers paid only 15% and beneficiaries paid 5%. The IRA restructured this model to protect enrollees, but it shifted roughly 60–65% of catastrophic cost liabilities directly onto private plans, heavily tightening insurer profit margins.
Phase 2: DOGE Audits and Executive Orders (2025–2026)
What turned this financial strain into a full-blown crisis was the policy shift under the current administration. With federal oversight moving from passive regulatory adjustments to aggressive fiscal crackdowns, the pressure intensified across both medical and pharmacy benefits.
The Department of Government Efficiency (DOGE) — leveraging direct read-only access to CMS payment databases, the Acquisition Lifecycle Management system (CALM), and the Healthcare Integrated General Ledger Accounting System (HIGLAS) — launched a sweeping effort against what it calls “big money fraud” in Medicare Advantage. DOGE and the HHS Office of Inspector General (OIG) significantly scaled up Risk Adjustment Data Validation (RADV) audits to claw back billions of dollars in alleged overpayments, hitting major insurers like Kaiser Permanente ($556 million) and Aetna ($117.7 million) with substantial financial settlements that slowed baseline federal funding.
Concurrently, President Trump issued Executive Order 14273, which kept the core framework of the Medicare Drug Price Negotiation Program intact while directing key administrative shifts. The order instructed federal agencies to adjust drug policies across four primary areas:
- Fixing the “Pill Penalty” (Section 3): Under the IRA, traditional daily pill medications become subject to government price negotiations sooner (7–9 years) than complex injectable “biologic” drugs (11–13 years). To protect small-molecule drug development, the order directs HHS to work with Congress to equalize these negotiation timelines.
- Passing Discounted Insulin Directly to Patients (Section 7): Requires community health centers receiving federal grants under the 340B drug program to pass wholesale discounts directly to uninsured or low-income patients, capping their out-of-pocket costs for insulin and injectable epinephrine (EpiPens).
- Canadian Drug Importation (Section 10): Directs the FDA to simplify the approval process for states seeking to import lower-cost prescription drugs in bulk from Canada and other foreign markets.
- Targeting Middlemen and Speeding Up Generic Approvals (Sections 8, 9 & 13): Instructs federal regulators (HHS, FTC, and DOJ) to investigate Pharmacy Benefit Managers (PBMs) for anti-competitive pricing while directing the FDA to accelerate regulatory approvals for generic drugs and biosimilars to increase market competition.
Phase 3: CMS Policy Shifts & Standalone Part D Premium Pressures (2026)
Alongside these executive directives, CMS made a major administrative decision on July 28, 2026, independently announcing the formal conclusion of the temporary Biden-era Part D Premium Stabilization Demonstration program at the end of calendar year 2026.
Because this program was created through CMS’s internal regulatory “demonstration authority” (rather than permanent federal legislation), CMS held the administrative power to end it. Originally launched with $9.8 billion in funding across 2025–2026 to cushion insurers against the IRA’s new $2,000 out-of-pocket cap, this subsidy artificially bought down monthly premiums and limited annual rate increases.
The end of these subsidies creates a stark divergence between plan types:
- Standalone Part D Plans (PDPs) Face Rising Premiums: Beneficiaries enrolled in standalone Part D plans — typically those with Original Medicare or Medicare Supplement (Medigap) plans — represent the primary group at risk for higher premiums. Because standalone plans only offer prescription coverage and cannot pull revenue from medical or hospital benefits, their primary mechanism to absorb higher catastrophic drug liabilities is raising monthly premiums or tightening plan formularies. Without the federal subsidy cushion, insurance providers will set their 2027 bids based purely on actual costs, which experts predict will trigger higher monthly premiums and reduced plan options.
- Medicare Advantage (MA-PD) Plans Shielded: Seniors enrolled in Medicare Advantage plans with integrated drug coverage are generally shielded from these sharp premium hikes. Unlike standalone plans, Medicare Advantage insurers receive comprehensive capitated payments across medical, hospital, and drug benefits. They can utilize extra rebate dollars generated from medical care management to subsidize their prescription coverage, allowing many MA plans to maintain low or $0 monthly drug premiums.
- Remaining Statutory Safeguards: Standard Part D plans remain subject to a statutory 6% cap on annual growth for the Part D Base Beneficiary Premium. However, because this cap applies to the national baseline average, individual plans can still adjust specific monthly prices above or below that average depending on their drug lists and plan designs.
Phase 4: Physician Fee Schedule Cuts
The 2026 Efficiency Cuts
Despite a nominal legislative payment bump passed in Congress, the 2026 Medicare Physician Fee Schedule (PFS) finalized a negative 2.5% “efficiency adjustment” across thousands of physician services, alongside a 7% drop in practice-expense payments for services performed in facilities like hospitals and surgical centers.
The 2027 Conversion Factor Drop
The newly proposed CY 2027 Physician Fee Schedule claws back the temporary 2.5% legislative increase, setting up a net -2.5% baseline reduction in Medicare payments compared to 2026, alongside further rate cuts for clinicians.
Phase 5: The Trickle-Down Squeeze and the Breakup on the Ground
When the federal government squeezes the top of the pyramid, the pressure moves downward. To protect falling profit margins from DOGE audits, v28 risk changes, lost Part D subsidies, and higher medication liabilities, major insurance carriers are taking drastic action — slashing the reimbursement rates they pay to doctors and hospitals, and multiplying administrative hurdles like prior authorizations to delay or deny care.
But providers are already dealing with their own soaring operational costs, labor shortages, and federal PFS cuts. When an insurer says, “we are paying you less for this surgery,” the doctor or hospital system reaches a breaking point. Instead of accepting terms that would force them to operate at a loss, prominent health systems are dropping their Medicare Advantage contracts entirely.
The Cascade: A Quick Reference
| Phase | Key Driver | Direct Mechanism | Cascading Impact on Patients |
|---|---|---|---|
| 1. The Baseline | v28 Risk Model & IRA | Limits risk-adjusted payments; shifts high drug costs to insurers. | Insurers face lower base margins on millions of beneficiaries. |
| 2. Executive & Audit Shifts | DOGE, EO 14273 & RADV Audits | Deep access to HIGLAS/CALM; aggressive clawbacks; fixes to “pill penalty”. | Insurers face settlement penalties, shifting drug rules, and reduced federal cash flow. |
| 3. Subsidy Expiration | CMS End to Part D Demonstration | Retires $9.8B in temporary premium buy-down subsidies for Part D plans. | Standalone PDP premiums rise for Original Medicare/Medigap users; MA plans absorb via rebates. |
| 4. The Provider Squeeze | Physician Fee Schedule Cuts | Negative 2.5% efficiency cuts; 7% cuts to facility-based services. | Hospitals and clinics lose the financial buffer to accept lower rates. |
| 5. The Breakup | Insurers cut rates; providers walk away | Insurers squeeze doctors to preserve margins; doctors drop MA contracts. | Seniors are left with out-of-network notices and disrupted care. |
The Bottom Line
The aggressive focus on government efficiency, regulatory shifts, and spending cuts is directly colliding with the complex machinery of private-public Medicare. While the stated goal is targeting waste and encouraging market competition, the real-world execution is creating a chain reaction: government cuts squeeze the insurers, insurers squeeze local providers, providers walk away, and seniors are left paying the heaviest price in lost care, restricted networks, and higher standalone drug premiums.
Continue Reading — Part 2 of This Series
What does this systemic shift look like in practice? We break down the exact numbers, risks, and structural recommendations for a Miami-Dade beneficiary navigating this network volatility. Read Part 2: Miami-Dade Case Study →Unsure which Medicare plan protects you best in South Florida’s shifting network?
Get a Free Medicare ConsultationRelated reading: Medicare Plans in Florida · Medigap Comparison · Medicare Eligibility · Turning 65 Guide · Palm Bay Medicare
